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Abstract 
There is currently a surge for the development of novel photosensitizers (PSs) for photodynamic 
therapy (PDT) since those currently approved are not completely ideal. Among the tested 
compounds, we have previously investigated the use of Ru(II) polypyridyl complexes with a 
[Ru(bipy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ scaffold (bipy = 2,2'-bipyridine; dppz = 
dipyrido[3,2-a:2′,3′-c]-phenazine, phen = 1,10-phenanthroline). These complexes selectively 
target DNA. However, since DNA is ubiquitous, it would be of great interest to increase the 
selectivity of our PDT PSs by linking them to a targeting vector in view of targeted PDT. 
Herein, we present the synthesis, characterization and in-depth photophysical evaluation of a 
nanobody-containing Ru(II) polypyridyl conjugate selective for the epidermal growth factor 
receptor (EGFR) in view of targeted PDT. Using ICP-MS and confocal microscopy, we could 
demonstrate that our conjugate had a high selectivity for the EGFR receptor, which is a crucial 
oncological target as it is overexpressed and/or deregulated in a variety of solid tumors. 
However, contrary to expectations, this conjugate was found to not produce reactive oxygen 
species (ROS) in cancer cells and to be therefore not phototoxic. 
 
Graphical abstract 
The synthesis, characterization and in-depth photophysical evaluation of a nanobody-
containing Ru(II) polypyridyl conjugate selective for the epidermal growth factor receptor 
(EGFR) in view of targeted PDT is presented. 
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Introduction 
The use of photodynamic therapy (PDT) has expanded the possible techniques in medicine to 
treat various types of cancer (e.g., lung, bladder, oesophageal and brain cancer) as well as 
bacterial, fungal or viral infections. Its effect is caused by a combination of an ideally non-toxic 
photosensitizer (PS), oxygen and light. Upon light exposure, the PS is able to produce reactive 
oxygen species (ROS), such as singlet oxygen (1O2) or other radicals. Due to the high reactivity 
of the latter, these can cause oxidative stress and damage in different cellular compartments 
(e.g., membrane, nucleus, endoplasmic reticulum, lysosome, mitochondria), leading ultimately 
to cell death.[1]  
Next to the already approved PDT PSs, which are based on a tetrapyrrolic scaﬀold (i.e. 
porphyrins, chlorins, phthalocyanines), the development of Ru(II) polypyridyl complexes as 
PDT PSs is receiving more attention due to their ideal photophysical and photochemical 
properties, which include, among others, high water solubility, high chemical stability and 
photostability, intense luminescence, large Stokes shifts, high 1O2 production.[1a-d, 2] These 
attractive features have allowed one of such complexes, namely TLD-1433, to enter into clinical 
trial as a PDT PS against bladder cancer.[3] Phase I has been recently completed.[2f] 
In this context, our group was able to demonstrate that Ru(II) complexes of the type 
[Ru(bipy)2(dppz)]2+ (bipy = 2,2'-bipyridine, dppz = dipyrido[3,2-a:2′,3′-c]-phenazine) and 
[Ru(phen)2(dppz)]2+ (phen = 1,10-phenanthroline) were effective PDT PSs (Figure 1).[1a, 2c, 4] 
As a highlight, we could demonstrate that some of these complexes were non-toxic in the dark 
and highly toxic upon light irradiation with IC50 values in the low micromolar range and a 
phototoxic index of up to >150.[2c] Based on the extended planar π-system of the dppz ligand, 
which is able to intercalate into the base pairs of the DNA, these compounds showed a 
preferable nuclear localization. Upon light exposure, these complexes caused oxidative stress, 
as well as DNA photocleavage, suggesting that they impaired replication and integrity of the 
genetic material.[1a, 2c, 4]  
Highly proliferating cells like cancer cells are generally preferably targeted by such compounds 
over healthy cells, as it is the case for cisplatin.[5] However, other frequently dividing cells in 
the organism (e.g. hair follicles, gastrointestinal tract, bone marrow) can be affected, leading to 
severe side-effects for the patients.[4a, 6] Thus, it is extremely important to increase the 
selectivity of PDT PS, for example, with the development of a suitable delivery system. 
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Figure 1. Structures of [Ru(bipy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ complexes as PSs 
developed by our group.[1a, 2c, 4] 
 
 
So far, the examples of Ru(II) polypyridyl complexes for targeted PDT are scare, if we do not 
take into account polymer encapsulation/nanoparticle attachment.[4a, 7] The group of Lilge could 
recently demonstrate that the premixing of TLD-1433 with transferrin was able to increase the 
extinction coefficient, prolongs the absorption range, reduced photobleaching, cellular uptake 
as well as overall toxicity of the compound.[8] Our group previously demonstrated the efficiency 
of the coupling of a metal-based PDT PS to peptides, which are known to bind specifically to 
abundant molecular targets on malignant cells. More precisely, in those studies, bombesin, that 
is known to target the human gastrin-releasing peptide receptor as well as a nuclear localization 
signal peptide that facilitates the intracellular transport into the nucleus were coupled to Ru-
based PDT PSs. We were able to demonstrate an increased uptake of the conjugate in the 
receptor-expressing cells in comparison to the free complex.[4a] The groups of Weil and Rau 
were able to link the peptide hormone somatostatin to a PS and could show an 100-fold 
increased efficiency for somatostatin receptor-expressing cells compared to the free PS.[7a] 
Recently, the authors described a macromolecular plasma protein serum albumin–PS conjugate 
with several Ru complexes bound to the protein surface. Using the protein as a nanocarrier, the 
PSs were delivered selectively to the mitochondria, where it showed an impressive 
phototoxicity with IC50 values in the nanomolar range.[7c] Worthy of note, a variety metal 
complexes as for example Re(I), Pt(II), Ru(II) or Ir(III) compounds have been successfully 
coupled to peptides to increase receptor selectivity.[9]  
Among the different established classes of delivery systems[10] (e.g. oil-dispersions, 
encapsulation in polymeric particles/lysosomes, targeting peptide-PS conjugates, polymer-PS 
conjugates), the conjugation of PS to monoclonal antibodies (mAb) takes advantage of the 
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excellent target specificity of the latter. However, despite their clinical success, the concept of 
utilizing mAb-PS conjugates is afflicted with several important drawbacks. These vector 
molecules are known for their high stability and prolonged serum half-life, slow 
pharmacokinetics and clearance from the body. This leads to an increase of the absolute level 
of the mAb-PS conjugate in the tumor alongside with an increased non-specific uptake in non-
target tissues.[11] Additionally, the treatment of solid tumors is limited due to penetration 
problems of the large conjugate into the tumor caused by poor vascularization, drainage, 
interstitial pressure and dense stroma.[12] An attractive strategy to circumvent these limitations 
is the use of smaller oncotropic vector molecules like antibody fragments or nanobodies 
(NBs).[13] NBs represent the antigen-binding domain of heavy-chain-only antibodies that occur 
in species belonging to the family of Camilidae. Their small size, stability, solubility, fast 
pharmacokinetics as well as high specificity and affinity for their cognate antigens make them 
powerful targeting agents for diagnostic imaging and targeted therapy.[14] Noteworthy in this 
context, Caplacizumab, a bivalent anti-von Willebrand factor NB, is currently in Phase III 
clinical trials against acquired thrombotic thrombocytopenic purpura.[15]  
A recent study has highlighted the high tumor uptake, rapid blood clearance and low liver 
uptake of a 99mTc-labed NB as an imaging probe for epidermal growth factor receptor (EGFR) 
positive tumors.[16] This receptor, which is involved in many cellular processes such as 
proliferation, differentiation and cell survival, represents a crucial target in oncology as it is 
overexpressed and/or deregulated in a variety of solid tumors, including head and neck, breast, 
non-small-cell lung and pancreatic cancer. Therefore, EGFR is a major target for cancer 
therapy.[16-17] Worthy of note, the successful conjugation of the PS IRDye700DX–maleimide 
to nanobodies for hepatocyte growth factor receptor targeted PDT was recently 
demonstrated.[18]  
With this in mind, we report herein the design, synthesis, characterization and in-depth 
biological evaluation of a NB-containing Ru(II) polypyridyl conjugate. The conjugate consists 
of three building blocks: 1) a [Ru(phen)2(dppz)]2+ complex, which is known to have an 
excellent phototoxicity[1a, 2c, 4], 2) a 7C12 NB, which is known for specific binding to EGFR 
expressing cells[16, 19] and 3) a peptide chain with a poly-glycine unit, which is necessary for an 
efficient and site-specific conjugation by a sortase A (SrtA)-mediated trans-peptidation reaction 
leading to an 1:1 NB:PS ratio.[20] To the best of our knowledge, we report herein the first NB-
containing Ru(II) polypyridyl conjugate as a PDT PS for EGFR-targeted PDT. As can be seen 
below, thanks to this design, a highly selective NB-containing [Ru(phen)2(dppz)]2+ conjugate 
Ru-NB could be unveiled. 
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Results and discussion 
 
Synthesis of the [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)] complex 
The synthetic strategy for the synthesis of the [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-
(Ser)2(Gly)5-NH3)]3+ complex is described in Scheme 1.  
 
 
Scheme 1. Total synthesis of [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-
NH3)](TFA)3. a) EtOH, reflux 3 h, DMSO, 150°C 2 h; b) 1,10-phenanthroline, LiCl, DMF, 
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reflux overnight under N2 atmosphere; c) 1,10-phenanthroline, KBr, H2SO4, HNO3, 90°C 3 h 
under N2 atmosphere; d) EtOH, 80°C 3 h under N2 atmosphere; e) LiAlH4, THF, 60°C 1 h under 
N2 atmosphere; f) acetic acid, CH3CN, reflux 1 h under N2 atmosphere; g) (COCl)2, DMF, 
CH3CN, RT, overnight under N2 atmosphere; h) Phthalimide, K2CO3, DMF, RT, overnight; i) 
NH2NH2, MeOH, reflux overnight under N2 atmosphere; j) maleic anhydride, AcOH, reflux 
10 h under N2 atmosphere; k) (NH3-(Gly)5-(Ser)2-Cys-CONH2)(TFA), CH3CN:H2O 1:1, RT, 
30 h. 
 
The [Ru(phen)2(dppz-7-aminomethyl)](PF6)2 complex was synthesized as previously reported 
in nine synthetic steps.[4a] The synthesis of the [Ru(phen)2(dppz-7-maleimidemethyl)](PF6)2 
complex is already published but, in this study, a slightly different experimental procedure was 
employed.[4a] The maleimide-containing Ru(II) complexes was prepared by reacting the 
[Ru(phen)2(dppz-7-aminomethyl)](PF6)2 complex with maleic anhydride. [Ru(phen)2(dppz-7-
maleimidemethyl)](PF6)2 was coupled to the poly-glycine chain via a thio-Michael addition 
reaction. As recently highlighted, this bioconjugation presents important advantages such as 
synthetic accessibility, excellent reactivity and, importantly, biocompatibility.[21] Following 
this synthetic strategy, the thiosuccinimide product [Ru(phen)2(dppz-7-maleimidemethyl-S-
Cys-(Ser)2-(Gly)5-NH3)]3+ was prepared by reacting thiol of the (NH3-(Gly)5-(Ser)2-Cys-
CONH2)(TFA) peptide chain with the [Ru(phen)2(dppz-7-maleimidemethyl)](PF6)2 complex. 
The product was obtained after an overnight reaction at room temperature and isolated via 
preparative HPLC. The identity of the obtained complexes was confirmed by HR-MS and the 
purity verified by HPLC (Figures S1-S2). We note that S-maleimide adducts[22] have been 
found to have some problems of stability and this is the reason why alternative conjugation 
techniques are currently sought. 
 
Sortase A-mediated conjugation 
Site-specific attachment of the [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2-(Gly)5-
NH3)]3+ complex to the EGFR-specific NB 7C12 by Sortase A requires protein engineering to 
endow the desired conjugation site at the C-terminal end of the NB with the unique sortase 
recognition motif. To this end, the NB was produced with its C-terminus tagged with a 
(GGGGS)3 spacer followed by a Strep-tag, the LPETGG sortase motif, another (GGGGS)3 
spacer and a hexahistidine purification tag (His6). As successful sortase A-mediated 
conjugation leads to the elimination of the His6-tag, this design allows the removal of the 
unreacted NB as well as of the His6-tagged enzyme by affinity chromatography (Scheme 2). 
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Scheme 2. Overview of the Sortase A-mediated site-specific modification of the NB derivative 
7C12-Strep-Sortag-His6 with the Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-
NH2) complex resulting in Ru-NB conjugate. The [Ru(phen)2(dppz)]2+ complex is highlighted 
in green, while the engineered NB is drawn in red and the peptide chain with a poly-glycine 
unit is depicted in blue. PDB entry of Sortase A from Staphylococcus aureus: 1T2P.[23] 
 
To optimize the sortase-mediated bioconjugation reaction, the molar ratios of SrtA, NB and 
[Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)]3+ as well as the reaction time 
were varied (see Figures S3-S4). A 4 h reaction at 30°C with a molar ratio of 1:1:10 was 
identified as being ideal (Figure 2). 
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Figure 2. Course of reaction for the chemoenzymatic conjugation of [Ru(phen)2(dppz-7-
maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)]3+ to the EGFR-specific NB 7C12. While the molar 
ratio between SrtA and NB was kept constant (1:1), the amount of the Ru(II) precursor was 
increased (10-100 nmol) to finally achieve molar ratios of 1:1:1, 1:1:2, 1:1:5 and 1:1:10, 
respectively. The reaction was monitored for up to 4 h and aliquots were separated on 15% SDS 
polyacrylamide gels. After electrophoresis, gels were imaged with a D-DiGit Gel Scanner (B) 
to detect the signal of the Ru(II) complex and subsequently stained with colloidal Coomassie 
G-250 (A). 
 
Consequently, these conditions were kept in an upscaled reaction using 2 µmol SrtA, 2 µmol 
sdAb and 20 µmol [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)]3+. After 
purification of the reaction mixture by affinity chromatography, the obtained conjugate 7C12-
Strep-[Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)]3+ (Ru-NB) was 
analyzed by MALDI-TOF MS (Figure S5). The mass spectra of the final purified product Ru-
NB showed a homogeneous population of a single-conjugated NB with a molecular mass of 
~17.7 kDa.  
 
 
Photophysical properties 
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With the conjugate in hand, we performed photophysical measurements to evaluate its potential 
as a PDT agent. At first, the absorptions of [Ru(phen)2(dppz-7-maleimidemethyl)](PF6)2, 
[Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)](TFA)3 and Ru-NB were 
measured to investigate if the peptide chain or the NB conjugation had an influence on the 
photophysical properties of the Ru(II) polypyridyl complexes. Since the conjugate is insoluble 
in CH3CN, the measurement of Ru-NB was performed in DMSO. The comparison between the 
absorption spectra (Figure S6) shows small differences in intensity as well as a small shift of 
the absorption band which can be explained by solvent effects. Since all major bands are still 
comparable, we assume that the conjugation did not change the photophysical properties of the 
Ru(II) polypyridyl complex. As a second experiment, the emission and luminescence of the 
conjugate was investigated upon excitation at 450 nm in DMSO. The maximum of the emission 
of the complex (Figure S7) was determined to be 633 nm. Consequently, there is a large Stokes 
shift which results in minimal interference between excitation and luminescence. The 
luminescence quantum yield (Φem) was measured upon excitation at 450 nm by comparison 
with the model complex [Ru(bipy)3]Cl2 in CH3CN (Φem = 5.9%).[24] The luminescence quantum 
yield (Φem) of the conjugate Ru-NB with a value of 3.3% was found to be in the same range 
than complexes of the type [Ru(bipy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+.[2c, 4] For a deeper 
investigation of the excited state, the luminescence lifetimes were determined in degassed and 
air saturated DMSO upon excitation at 450 nm to investigate the influence of the presence of 
oxygen. As expected, the luminescence lifetime in a degassed solution was much longer (589 
ns, Figure S8) than in an aerated solution (134 ns, Figure S9). This shows that oxygen has a 
significant influence on the lifetime of the excited state and indicates that 3O2 can interact with 
the triplet state of the complex. 
 
Singlet oxygen generation 
Knowing that the triplet excited state of the conjugates are able to interact with oxygen, we 
were interested in determining the singlet oxygen quantum yield Φ(1O2) of Ru-NB using two 
methods previously described by our group,[25] namely: 1) by direct method by measurement 
of the phosphorescence of 1O2 at 1270 nm. Worthy of note, this method is dependent on the 
used setup. With the used equipment in our laboratory, we can only detect Φ(1O2) > 0.20; 2) by 
indirect method by measurement of the change in absorbance of a reporter molecule which is 
monitored by UV/VIS spectroscopy. Since the measurements were performed in DMSO and 
aqueous solution, only rather small values (Table 1) could be measured. This is not surprising 
and has already been investigated for several other [Ru(bipy)2(dppz)]2+ and 
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[Ru(phen)2(dppz)]2+ complex derivatives.[2c, 4a, 4b] In-depth investigations showed that the 
excited state of the complex is quenched in an aqueous solution due to hydrogen bonding 
interactions between the nitrogen atoms of the dppz ligand and the solvent.[26] Comparison of 
the singlet oxygen quantum yield of Ru-NB with the ones obtained for structurally related 
[Ru(bipy)2(dppz)]2+ complexes[2c], revealed that these values are in the same range. This 
strongly suggests that the bioconjugation did not significantly influence this property. 
 
Table 1. Singlet oxygen quantum yields (Φ(1O2)) of Ru-NB in DMSO and aqueous solution 
determined by direct and indirect method by excitation at 450 nm. Average of three independent 
measurements, +-10% (n.d.=not detectable). 
Compound DMSO 
direct 
D2O 
direct 
DMSO 
Indirect 
PBS 
Indirect 
Ru-NB n.d. n.d. 9% 4% 
 
 
In vitro evaluation of EGFR targeting after conjugation 
In order to investigate the targeting ability of the functionalized NB, uptake in the human 
epithelial cell line A431 originating from an epidermoid carcinoma of the skin was examined 
by confocal fluorescence microscopy. These squamous carcinoma cells express approximately 
2 x 106 EGFR molecules per cell[27], which represents a high expression level. Confocal 
imaging of A431 cells showed co-localization of Ru-NB with EGFR (Figure 3), thus indicating 
the preserved targeting ability of 7C12 after site-specific modification. Noteworthy, Ru-NB 
showed a predominant membrane staining even after 48 h of incubation at 37°C, and only very 
little intracellular fluorescence was observed. However, it has been shown recently that the free 
amine ruthenium complex is characterized by a poor cellular uptake even at high micromolar 
concentrations.[4a] 
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Figure 3. Confocal immunofluorescence microscopy images of A431 cells exposed to Ru-NB 
for 4, 24 and 48 h at 37°C showing specific binding and co-localization of the single-conjugated 
NB with EGFR.  
 
Cellular uptake of the bioconjugates 
The presence of a metal ubiquitous in a cellular environment as an essential component of the 
PS allows investigating the cellular accumulation of the bioconjugate by inductively coupled 
plasma- mass spectrometry (ICP-MS).[28] In order to demonstrate the receptor-specific uptake, 
EGFR-positive (A431) and EGFR-negative (MDA-MB-435S) cells were incubated for 
different periods of time (4, 24, and 48 h) with different concentrations of the bioconjugate in 
the dark at 37°C. The amount of cell-associated ruthenium was determined by ICP-MS and 
related to the cellular protein content (Figure 4). Although ruthenium was detectable in the cell 
lysate of both cell lines after 24 and 48 h, respectively, the amount of the metal strongly 
correlated with the level of EGFR expression. There was more of ruthenium in the EGFR-
overexpressing cell line than in the EGFR-negative one. This finding confirmed that cell 
association was primarily mediated by the NB and not by the PS. 
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Figure 4. Amount of cell-associated ruthenium after incubation of EGFR-positive A431 and 
EGFR-negative MDA-MB-435S cells with 2 or 20 µM of Ru-NB for up to 48 h at 37°C. The 
level of ruthenium in cell lysates of MDA-MB-435S exposed to 2 µM of Ru-NB were below 
the analytical limit and are thus not shown.  
 
An identical cell uptake study was performed with the complex [Ru(bipy)2(dppz-OMe)](PF6)2, 
resulting in comparable ruthenium levels for the A431 cell line (Figure S10 and Table 2). The 
amount of ruthenium detected in MDA-MB-435S cells upon incubation with this non-targeted 
Ru-complex was higher at each time point compared to the EGFR-targeting Ru-NB conjugate. 
This result is unsurprising as the latter cells lack these receptor proteins at their surface. 
 
Table 2. Head-to-head comparison of uptake of Ru-NB and [Ru(bipy)2(DPPZ-OMe)](PF6)2 
into A431 and MDA-MB 435S cells. The amount of cell-associated ruthenium [ng/mg protein] 
was measured by ICP-MS. 
 
 Ru-NB Ru(bipy)2(DPPZ-OMe) (PF6)2 
 
 A431 MDA-MB 453S A431 
MDA-MB 
453S 
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Time 
[h] Concentration of substance [µM] 
 
 2 20 2 20 2 20 2 20 
4 3.26 ± 1.30 
11.67 ± 
1.70 < LOD < LOD 
1.20 ± 
0.28 
8.54 ± 
2.23 
1.18 ± 
0.14 
5.20 ± 
0.90 
24 6.20 ± 1.86 
23.84 ± 
1.54 < LOD 
5.52 ± 
2.00 
2.51 ± 
0.19 
18.83 ± 
2.84 
1.84 ± 
0.05 
15.84 ± 
2.69 
48 11.54 ± 1.89 
32.87 ± 
4.87 < LOD 
5.45 ± 
1.32 
5.75 ± 
0.74 
46.94 ± 
1.89 
1.92 ± 
0.08 
19.93 ± 
2.39 
 
To confirm the receptor specificity of the ruthenium accumulation, A431 cells were incubated 
in the presence or absence of cetuximab in addition to Ru-NB. The epitope for 7C12 partially 
overlaps the cetuximab epitope on domain III of the EGFR extracellular region and an excess 
of the mAb can block its interaction with the receptor.[16, 29] After 24 and 48 h of incubation 
with 200 nM of Ru-NB at 37°C, 0.77 ng and 2.74 ng ruthenium per mg protein (Table 3), 
respectively, were detected in the cell lysates. Upon co-incubation of EGFR-overexpressing 
A431 cells with Ru-NB and cetuximab, no cell-associated ruthenium was detectable even after 
48 h. 
 
Table 3. Amount of cell-associated ruthenium after incubation of EGFR-positive A431 with 
200 nM of Ru-NB for 24 or 48 h at 37°C. The level of ruthenium in cell lysates of A431 co-
incubated with 1 µM of the EGFR-blocking antibody cetuximab were below the limit of 
detection (LOD). 
Ru-NB 200 nM 200 nM 
Cetuximab - 1 µM 
 ng Ru per mg protein 
24 h 0.77 ± 0.10 < LOD 
48 h 2.74 ± 0.12 < LOD 
 
These latter findings corroborate the hypothesis that cellular ruthenium association occurs in a 
receptor-mediated manner. Overall, Ru-NB targets EGFR specifically. Importantly, the free 
water-soluble PS exhibits only poor cell binding capacity and lacks cell line selectivity, until 
their conjugation to targeting moieties. These facts together strongly provide the basis for 
tumor-specific PDT.  
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Dark cytotoxicity and phototoxicity of Ru-NB  
To evaluate the potency of the bioconjugate Ru-NB as a PDT agent, its cytotoxicity in the dark 
and upon light irradiation was determined. For these experiments, the A431 cell line had to be 
chose due to the strong light sensitivity of the MDA-MB-435S (EGFR negative) cell line that 
precluded it from phototoxicity studies. To avoid light sensitivity in A431 cell line, irradiation 
at 480 nm was performed in sequences. 6 x 3.5 min of irradiation with 15 min gap in between 
(6.741 J cm-2) were used. Dark treatment and surprisingly light irradiation of the A431 cells 
(48 h incubation with Ru-NB) at 480 nm did not cause any cytotoxic effect (IC50 dark >25 µM, 
IC50 light >25 µM, see Figure S11) for Ru-NB. We note that we could not go for higher 
concentration due to conjugate precipitation at 50 µM. Adding polyethylene glycol spacers, 
changing the ionic strength or the pH could possibly affect the conjugate solubility, and 
consequently help solving this problem.  Lack of cytotoxicity encouraged us to try to enhance 
the internalization of the conjugate into the cells. For that purpose, an additional step was used, 
namely temperature change.[30] Cells treated with Ru-NB were incubated for 1 h at 4 ºC. Since 
EGFR internalization is an energy-dependent process, incubating cells at 4ºC inhibits the 
endocytosis processes but not the binding of Ru-NB to the receptor. A temperature shift to 37ºC 
(for 1 h) allowed then for efficient endocytosis of the receptor with the bound conjugate. This 
step enables a higher accumulation of Ru-NB in the cells. Due to conjugate precipitation, the 
highest concentration tested was 35 µM. Ru-NB was again found to be non-toxic in the dark 
(IC50 >35 µM.) Unfortunately, light irradiation at 480 nm (6 x 3.5 min with 15 min gap between 
irradiations) again did not cause any phototoxic effect (IC50 >35 µM, see Figure S12).  
 
Cellular ROS production by Ru-NB 
The lack of phototoxicity of Ru-NB led us to investigate whether this conjugate could produce 
ROS in irradiated cells. For that purpose, we have stained A431 cells with the known ROS 
probe DCFH-DA (2′,7′-dichlorodihydrofluorescein diacetate). Cells were then treated with Ru-
NB (35 µM) using the receptor internalisation protocol, irradiated (480 nm light for 3.5 min; 
1,124 J cm-2) and suspended in PBS buffer. The DCFH-DA signal was detected using flow 
cytometry instrument. As can be seen in Figure S13, there was no ROS production in the A431 
cells that were treated with Ru-NB and then irradiated, as distinct from the H2O2 treated control. 
This unexpected result might be caused by the impairment of the internalization of Ru-NB into 
the cells. Another explanation would be that the ROS produced are directly reacting with the 
NB itself. However, this hypothesis is unlikely since 1O2 was detected during the 1O2 production 
measurements.   
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Conclusion 
In summary, in this article, we present the synthesis, characterization and photophysical and 
biological evaluation of a novel nanobody containing Ru(II) polypyridine conjugate. As a 
benefit of the linkage to a 7C12 nanobody, the conjugate selectively accumulated at the 
epidermal growth factor receptor (EGFR). The investigation of the uptake via ICP-MS 
indicated that the conjugate has been successfully internalized inside cancerous A431 cells. 
Photophysical studies in cuvette suggested that the photophysical properties of the conjugate 
remain unchanged in comparison to the compound alone. However, DCFH-DA staining 
experiments indicated that no significant ROS was produced inside the cells. Consequently, 
photocytotoxicity investigations did not show any significant effect. Focus of future work will 
be the successful development of a nanobody-containing Ru(II) polypyridine conjugate with 
ROS and photocytotoxicity inside cancerous cells. 
 
 
 
Experimental  
 
Materials 
All chemicals were obtained from commercial sources and were used without further 
purification. Solvents were dried over molecular sieves if necessary. The ligand 5-
(aminomethyl)-2,2′-bipyridine[31] and the Ru(II) complexes [Ru(bphen)2Cl2] using the 
respective ligands[32], [Ru(phen)2(dppz-7-aminomethyl)](PF6)2 were synthesized as previously 
reported.[4a]  
 
Instrumentation and methods 
1H and 13C NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer. ESI-MS 
experiments were carried out using a LTQ-Orbitrap XL from Thermo Scientific (Thermo Fisher 
Scientific, Courtaboeuf, France) and operated in positive ionization mode, with a spray voltage 
at 3.6 kV. No Sheath and auxiliary gas was used. Applied voltages were 40 and 100 V for the 
ion transfer capillary and the tube lens, respectively. The ion transfer capillary was held at 
275°C. Detection was achieved in the Orbitrap with a resolution set to 100,000 (at m/z 400) and 
a m/z range between 150-2000 in profile mode. Spectrum was analyzed using the acquisition 
software XCalibur 2.1 (Thermo Fisher Scientific). The automatic gain control (AGC) allowed 
accumulation of up to 2*105 ions for FTMS scans, Maximum injection time was set to 300 ms 
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and 1 µscan was acquired. 10 µL was injected using a Thermo Finnigan Surveyor HPLC system 
(Thermo Fisher Scientific) with a continuous infusion of methanol at 100 µL.min-1. For analytic 
and preparative HPLC the following system has been used: 2 x Agilent G1361 1260 Prep Pump 
system with Agilent G7115A 1260 DAD WR Detector equipped with an Agilent Pursuit XRs 
5C18 (Analytic: 100Å, C18 5 μm 250 x 4.6 mm, Preparative: 100Å, C18 5 μm 250 x 300 mm) 
Column and an Agilent G1364B 1260-FC fraction collector. The solvents (HPLC grade) were 
millipore water (0.1% TFA, solvent A) and acetonitrile (0.1% TFA, solvent B). The sample 
was dissolved in 1:1 (v/v) CH3CN/ H2O 0.1% TFA solution and filtered through a 0.2 μm 
membrane filter. Gradient: 0-3 minutes: isocratic 95% A (5% B); 3- 17 minutes: linear gradient 
from 95% A (5% B) to 0% A (100% B); 17-25 minutes: isocratic 0% A (100% B). The flow 
rate was 1 mL/min (for preparative purposes: 20 mL/min) and the chromatogram was detected 
at 250 nm, 350 nm, 450 nm. 
 
Synthesis 
[Ru(phen)2(dppz-7-maleimidemethyl)](PF6)2 
The synthesis of [Ru(phen)2-dppz-7-maleimidemethyl]2+ is already published[4a] but, in this 
study, a slightly different synthetic route was employed. [Ru(phen)2(dppz-7-
aminomethyl)](PF6)2 (25 mg, 1.0 equiv.) and maleic anhydride (46 mg, 20.0 equiv.) were 
suspended in acetic acid (10 mL) under a nitrogen atmosphere. The mixture was refluxed for 
10 h. The solution was then cooled down and a sat. aqueous solution of NH4PF6 was added. 
The crude product, which precipitated as a PF6 salt, was collected by filtration and washed three 
times with H2O and Et2O. The product was purified by column chromatography on silica gel 
with a CH3CN /aq. KNO3 (0.4 M) solution (10:1). The fractions containing the product were 
united and the solvent was removed. The residue was dissolved in CH3CN and undissolved 
KNO3 was removed by filtration. The solvent was removed and the product was dissolved in 
H2O. Upon addition of NH4PF6 the product precipitated as a PF6 salt. The solid was obtained 
by centrifugation and was washed with H2O and Et2O. Yield: 86%. Experimental data fits with 
the literature. Purity of the sample was assessed by NMR and HPLC analysis. RP-HPLC: Rt = 
16.2 min. 
 
[Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)](TFA)3 
[Ru(phen)2(dppz-7-maleimidemethyl)](PF6)2 (16 mg, 1.0 equiv.) and (NH2CO-Cys-
(Ser)2(Gly)5-NH3)(TFA) (11.6 mg, 1.2 equiv.) were dissolved in a 1:1 CH3CN/H2O mixture (20 
mL) and stirred in the dark at room temperature. The progress of the reaction was followed via 
19 
 
HPLC. After 24 h, additional (NH2CO-Cys-(Ser)2(Gly)5-NH3)(TFA) (4.8 mg, 0.5 equiv.) were 
added. The reaction mixture was stirred for another 6 h until the complete consumption of the 
Ru(II) complex was monitored. The solvent was removed under reduced pressure and the 
product was purified by preparative HPLC. The product was isolated as a red TFA salt. Purity 
of the sample was assessed by HPLC analysis. Yield: 95%. HRMS (ESI) m/z: Calcd. for 
[C66H62N18O12RuS-3TFA]3+: 445.7874, Found: 445.7875; RP-HPLC: Rt = 14.9 min. 
 
E. coli strains and plasmids 
Escherichia coli NEB 5-alpha (fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17) was used in molecular cloning experiments, whereas 
E. coli SHuffle® T7 Express (fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal λatt::pNEB3-r1-
cDsbC (SpecR, lacIq) ΔtrxB sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-210::Tn10 --
TetS) endA1 Δgor ∆(mcrC-mrr)114::IS10) and E. coli BL21(DE3) (fhuA2 [lon] ompT gal (λ 
DE3) [dcm] ∆hsdS) were used for expression of the recombinant proteins. All strains were 
purchase from New England Biolabs. The generation of pET-28b:7C12 encoding the EGFR-
specific single-domain antibody 7C12 has been previously described.[33] The plasmid 
pGBMCS-SortA was a gift from Fuyuhiko Inagaki (Addgene plasmid # 21931).[34] 
 
Molecular cloning 
A DNA fragment coding for a (GGGGS)3 spacer followed by a Strep-tag, the LPETGG sortase 
motif and another (GGGGS)3 spacer was commercially synthesized including a 5′ restriction 
site for HindIII and a 3′ restriction site for XhoI, respectively. The ~150-nt fragment was 
digested with appropriate restriction endonucleases and ligated in-frame into HindIII/XhoI-
linearized pET-28b:7C12 plasmid.[33] The ligation reactions were transformed into chemically 
competent E. coli NEB 5-alpha cells. The DNA sequences of the resulting recombinant 
construct pET-28b:7C12-Strep-Sortag-His6 were checked by Sanger sequencing. 
 
Cultivation and expression of recombinant proteins 
Freshly transformed E. coli SHuffle® T7 Express or E. coli BL21(DE3) harboring the plasmids 
pET-28b:7C12-Strep-Sortag-His6 or pGBMCS-SortA were inoculated in 10 mL of LB broth 
containing 50 μg/mL of kanamycin or 100 µg/mL of ampicillin, respectively, and cultivated at 
30°C overnight in an orbital shaker with 50 mm offset and shaking speed of 200 rpm. After 
that, 5 mL of this pre-culture were transferred into 125 mL MagicMedia™ E. coli Expression 
Medium (Life Technologies) in 1000 mL baffled-bottom glass flasks and grown at 30°C for 
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24 h. For final harvest, cultures were chilled on ice for 5 min and centrifuged for at least 15 min 
at 6,000 × g and 4°C. After removal of the supernatant, cell pellets were either stored at −20°C 
or subjected to purification procedure immediately. 
 
Purification of recombinant proteins 
A high-capacity Ni-iminodiacetic acid (IDA) resin in combination with an ÄKTA pure 
chromatography system (GE Healthcare) was used for purification of hexahistidine tagged 
proteins by immobilized metal affinity chromatography (IMAC) under native conditions. 
Efficient cell lysis was achieved by addition of 1 mL RIPA cell lysis buffer (G-Biosciences) 
supplemented with EDTA-free protease inhibitor cocktail (Roche Diagnostics), 500 µg 
lysozyme (Sigma-Aldrich) and 25 U endonuclease (Thermo Scientific Pierce) per 200 mg 
bacterial cell pellet. Prior to incubation on ice for at least 15 min, the pelleted cells were 
resuspended completely by vortexing or pipetting up and down until no cell clumps remained. 
After centrifugation at 10,000 x g and 4°C for 20 min to remove cellular debris, the clarified 
supernatant was loaded using an automated sample pump with a flow rate of 0.5 ml/min. IMAC 
was performed on a prefilled 5-ml His60 Ni Superflow cartridge (Clontech Laboratories) at a 
flow rate of 5 mL/min in equilibration buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5). Before 
elution of the hexahistidine tagged proteins by addition of 8 CV elution buffer (50 mM Tris-
HCl, 150 mM NaCl, 500 mM imidazole, pH 7.5), the column was washed with 8 CV 
equilibration buffer and 7 CV wash buffer (50 mM Tris-HCl, 150 mM NaCl, 35 mM imidazole, 
pH 7.5).Removal of imidazole and buffer exchange after IMAC was achieved by dialysis 
against sortase buffer (50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl2, pH 7.5) using a 
cellulose ester membrane with a molecular weight cut-off of 3.5-5 kDa (Spectrum® 
Laboratories). 
 
Gel electrophoresis 
Denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out according to a standard protocol.[35] For each gel, PageRuler Plus Prestained Protein 
Ladder (Thermo Fisher Scientific) was used as molecular weight ladder standard. After 
electrophoresis, gels were imaged with a D-DiGit Gel Scanner (LI-COR Biosciences) and 
subsequently stained with PageBlue protein staining solution (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. 
 
Protein determination 
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Protein concentration was determined with the DC Protein Assay (Bio-Rad Laboratories) 
according to the manufacture’s microplate assay protocol using bovine serum albumin in 
sortase buffer (50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl2, pH 7.5) as protein standard. 
 
Sortase A-mediated conjugation 
Small-scale reactions were set up in 100 µL with variable molar ratios of SrtA, 7C12-Strep-
Sortag-His6 and [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-NH3)]3+and 
different incubation times. The optimal conditions were upscaled and the reaction mixture was 
composed of 2 µmol SrtA, 2 µmol NB and 20 µmol [Ru(phen)2(dppz-7-maleimidemethyl-S-
Cys-(Ser)2(Gly)5-NH3)]3+ in sortase buffer (50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl2, 
pH 7.5). Bioconjugation reactions were incubated at 30°C for up to 6 h in the dark with gentle 
shaking.  
 
Purification of conjugation reactions 
In the first purification step, all remaining hexahistidine tagged proteins were eliminated from 
the reaction mixture by IMAC using prepacked His60 Ni Gravity Columns (Clontech 
Laboratories). After collection of the flow-through, the gravity-flow column was washed twice 
with equilibration buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5). These wash fractions as 
well as the flow-through were analyzed for the presence of the Ru-NB conjugate by SDS-
PAGE. Remaining unconjugated [Ru(phen)2(dppz-7-maleimidemethyl-S-Cys-(Ser)2(Gly)5-
NH3)]3+ was removed in a second purification step by size-exclusion chromatography using 
Zeba Spin Desalting Columns (7K MWCO, Thermo Scientific) with elution in PBS. The 
purified conjugate was sterile filtered using Whatman Puradisc FP 30 cellulose acetate syringe 
filter units with a pore size of 0.2 µm (GE Healthcare Life Sciences) and stored at 4°C. 
 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometry of purified sdAb-conjugates 
2,5-Dihydroxyactetophenone (2,5-DHAP, Bruker Daltonik) was used as matrix for MALDI-
TOF MS. For solubilization of the matrix, 7.6 mg of 2,5-DHAP were dissolved in 375 μL of 
absolute ethanol. After this, 125 μL of an 18 mg/mL aqueous solution of diammonium 
hydrogen citrate (Sigma-Aldrich) were added. Protein samples were desalted using mixed 
cellulose esters membrane filters with a pore size of 0.025 µm and a diameter of 25 mm (MF-
Millipore™ Membrane Filter VSWP, Merck Chemicals). Briefly, the filter was placed on the 
water surface of a beaker filled with distilled water. A 2 µL aliquot of the protein sample was 
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carefully pipetted on top of the membrane. After incubation at room temperature for at least 
10 min, 2 µL of the dialyzed sample was mixed with 2 µL of 2% TFA solution. After addition 
of 2 µL of the matrix solution, the mixture was pipetted up and down until the crystallization 
starts and the solution became cloudy. Finally, 0.5 µL of the crystal suspension was spotted 
onto the ground steel target plate and the droplet was air-dried completely at room temperature.  
Spectra were acquired with an autoflex II TOF/TOF (Bruker Daltonik) in positive linear mode 
in combination with the flexControl software (Version 3.3, Bruker Daltonik) and analyzed with 
the flexAnalysis software (Version 3.3, Bruker Daltonik). Theoretical molecular weights were 
calculated using the Compute pI/Mw tool on the ExPASy Server.[36] 
 
Spectroscopic measurements 
The absorption of the samples was measured in a cuvette with a Lambda 800 UV/VIS 
Spectrometer (PerkinElmer Instruments) or in 96 well plates with a SpectraMax M2 
Spectrometer (Molecular Devices). The emission was measured by irradiation of the sample in 
fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical 
parametric oscillator (Ekspla) at 450 nm. The luminescence was focused and collected at a right 
angle to the excitation pathway and directed to a Princeton Instruments Acton SP-2300i 
monochromator. As a detector a XPI-Max 4 CCD camera (Princeton Instruments) was used. 
 
Luminescence quantum yield measurements 
For the determination of the luminescence quantum yield, the samples were prepared in a 
CH3CN solution with an absorbance of 0.1 at 450 nm. This solution was irradiated in 
fluorescence quartz cuvettes (width 1 cm) using a NT342B OPO pulse laser Nd-YAG pumped 
optical parametric oscillator (Ekspla) at 450 nm. The emission signal was focused and collected 
at a right angle to the excitation pathway and directed to a Princeton Instruments Acton SP-
2300i monochromator. As a detector a XPI-Max 4 CCD camera (Princeton Instruments) was 
used. The luminescence quantum yields were determined by comparison with the reference 
[Ru(bipy)3]Cl2 in CH3CN (Φem=0.059)[24] applying the following formula: 
Φୣ୫,ୱୟ୫୮୪ୣ ൌ  Φୣ୫,୰ୣ୤ୣ୰ୣ୬ୡୣ ∗  𝐹୰ୣ୤ୣ୰ୣ୬ୡୣFୱୟ୫୮୪ୣ ∗
Iୱୟ୫୮୪ୣ
I୰ୣ୤ୣ୰ୣ୬ୡୣ  ∗ ൬
nୱୟ୫୮୪ୣ
n୰ୣ୤ୣ୰ୣ୬ୡୣ൰
ଶ
 
F ൌ  1 െ  10ି஺ 
 
Φem = luminescence quantum yield, F = fraction of light absorbed, I = integrated emission 
intensities, n = refractive index, A = absorbance of the sample at irradiation wavelength 
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Lifetime measurements 
For the determination of the lifetimes, the samples were prepared in an air saturated and in a 
degassed CH3CN solution with an absorbance of 0.1 at 450 nm. This solution was irradiated in 
fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical 
parametric oscillator (Ekspla) at 450 nm. The emission signal was focused and collected at a 
right angle to the excitation pathway and directed to a Princeton Instruments Acton SP-2300i 
monochromator. As a detector a R928 photomultiplier tube (Hamamatsu) was used. 
 
Singlet oxygen measurements  
- Direct evaluation 
The samples were prepared in an air saturated DMSO or D2O solution with an absorbance of 
0.2 at 450 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using 
a mounted M450LP1 LED (Thorlabs) whose irradiation, centred at 450 nm, was focused with 
aspheric condenser lenses. The intensity of the irradiation was varied using a T-Cube LED 
Driver (Thorlabs) and measured with an optical power and energy meter. The emission signal 
was focused and collected at a right angle to the excitation pathway and directed to a Princeton 
Instruments Acton SP-2300i monochromator. A longpass glass filter was placed in front of the 
monochromator entrance slit to cut off light at wavelengths shorter than 850 nm. The slits for 
detection were fully open. As a detector an EO-817L IR-sensitive liquid nitrogen cooled 
germanium diode detector (North Coast Scientific Corp.) was used. The singlet oxygen 
luminescence at 1270 nm was measured by recording spectra from 1100 to 1400 nm. For the 
data analysis, the singlet oxygen luminescence peaks at different irradiation intensities were 
integrated. The resulting areas were plotted against the percentage of the irradiation intensity 
and the slope of the linear regression calculated. The absorbance of the sample was corrected 
with an absorbance correction factor. As reference for the measurement in an CH3CN solution 
phenalenone (Φphenaleone=0.95)[37] and for the measurement in a D2O solution [Ru(bipy)3]Cl2 
(ΦRu(bipy)3Cl2=0.22)[38] was used and the singlet oxygen quantum yields were calculated using 
the following formula: 
Φୱୟ୫୮୪ୣ ൌ  Φ୰ୣ୤ୣ୰ୣ୬ୡୣ ∗  Sୱୟ୫୮୪ୣS୰ୣ୤ୣ୰ୣ୬ୡୣ ∗
I୰ୣ୤ୣ୰ୣ୬ୡୣ
Iୱୟ୫୮୪ୣ   
I ൌ  I଴  ∗  ሺ1 െ 10ି஺ ሻ 
Φ = singlet oxygen quantum yield, S = slope of the linear regression of the plot of the areas of 
the singlet oxygen luminescence peaks against the irradiation intensity, I = absorbance 
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correction factor, I0 = light intensity of the irradiation source, A = absorbance of the sample at 
irradiation wavelength. 
 
- Indirect evaluation 
For the measurement in DMSO: The samples were prepared in an air-saturated DMSO solution 
containing the complex with an absorbance of 0.2 at the irradiation wavelength and 1,3-
diphenylisobenzofuran (DPBF, 30 µM). For the measurement in PBS buffer: The samples were 
prepared in an air-saturated PBS solution containing the complex with an absorbance of 0.2 at 
the irradiation wavelength, N,N-dimethyl-4-nitrosoaniline aniline (RNO, 20 µM) and histidine 
(10 mM). The samples were irradiated on 96 well plates with an Atlas Photonics LUMOS BIO 
irradiator for different times. The absorbance of the samples was measured during these time 
intervals with a SpectraMax M2 Microplate Reader (Molecular Devices). The difference in 
absorbance (A0-A) at 415 nm for the DMSO solution and at 440 nm for the PBS solution was 
measured and plotted against the irradiation times. From the plot the slope of the linear 
regression was calculated as well as the absorbance correction factor determined. The singlet 
oxygen quantum yields were calculated using the same formulas as used for the direct 
evaluation.  
 
Cell culture 
Cell culture flasks, dishes and plates (CELLSTARS) were supplied by Greiner Bio-One GmbH. 
The adherent human tumor cell lines A431 (ATCC® number: CRL-1555) and MDA-MB 435S 
(ATCC® number: HTB-129) were maintained as previously reported.[32, 39] All cell lines were 
confirmed to be mycoplasma-negative using the Venor®GeM Advance Mycoplasma Detection 
Kit (Minerva Biolabs) and were tested monthly. 
 
Cell uptake studies 
A total of 300,000 MDA-MB 435S cells and 450,000 A431 cells were seeded in T25 cell culture 
flasks in 5 mL DMEM supplemented with 10% fetal calf serum (FCS), respectively, and 
incubated in a humidified atmosphere of 95% air/5% CO2 at 37°C. After 48 h of incubation, 
cells were washed twice with warm PBS. The buffer was then replaced by fresh DMEM 
supplemented with 10% FCS and different concentrations of the Ru-NB conjugate or 
Ru(bipy)2(DPPZ-OMe) (PF6)2. Following incubation at 37°C for certain time periods, medium 
was removed and the cells washed three times with warm PBS and trypsinized. After 
resuspension in warm DMEM with 10% FCS, the pellets were collected by centrifugation at 
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200 x g for 5 min and washed once with warm PBS. The cell pellets were resuspended in 500 μL 
of PBS, lysed by 10 freeze−thaw cycles, and sonicated in an ice-cold ultrasonic bath for 20 min 
(SONOREX SUPER 10P digital, Bandelin). After determination of the protein content, the 
lysates were lyophilized on an Alpha 2-4 LSC plus (CHRIST). 
 
ICP-MS studies 
After digestion of samples in distilled ultrapure 65% HNO3 (Roth) and dillution in 1% HNO3, 
ICP-MS measurements were performed on an iCap RQ ICP-MS spectrometer (Thermo Fisher  
Scientific) equipped with a SC-2DX autosampler (ESI). Calibration was done with Ru single 
element standard (Merck 170347). Rh and Sc were used as internal standards. Limit of detection 
(LOD) was 50 ng/L Ru. 
 
Confocal microscopy 
A total of 100,000 A431 cells were seeded in 35 mm imaging dishes (IBIDI) in 2 mL DMEM 
supplemented with 10% fetal calf serum (FCS), and incubated in a humidified atmosphere of 
95% air/5% CO2 at 37°C. After 24 h of incubation, media was refreshed and cells were 
incubated with 100 nM of Ru-NB at 37°C for up to 48 h. Afterwards, cells were washed thrice 
with ice-cold PBS, fixed with 4% paraformaldehyde and 2.5% sucrose in PBS, and 
permeabilized with 0.25% TritonX-100 in PBS for 10 min. To prevent unspecific antibody 
binding, cells were incubated with 10% FCS in PBS overnight at 4°C. Cells were then incubated 
with rabbit anti-EGFR (D38B1) Alexa Fluor® 647 monoclonal antibody (Cell Signaling 
Technology) and with StrepMAB-Classic Chromeo 488 conjugate (IBA Lifesciences) for 2 h 
at RT in the dark. Cells were again washed three times with PBS, and the nuclei were stained 
using Hoechst 33258. Fluorescence microscopy was performed with the Fluoview 1000 
confocal laser scanning microscope (Olympus) using a 60 × (NA 1.35) oil objective. 
 
Dark cytotoxicity and phototoxicity 
The dark and light cytotoxicity of the Ru(II)-containing conjugates was assesed by fluorometric 
cell viability assay using resazurin (ACROS Organics). For dark and light cytotoxicity with the 
EGFR internalisation step[40], A431 cells were seeded in triplicates in 96 well plates at a density 
of 4000 cells per well in 100 µl, 24 h prior to treatment. Cells were then treated with serum free 
DMEM media containing 0.3% of BSA for 1 h at 37 ºC. The medium was then replaced with 
increasing concentrations of Ru-NB, then cells were incubated on ice for 1 h. After that time, 
cells were transferred for 1 h at 37 ºC. The medium was then replaced by fresh complete 
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medium. For the dark and light cytotoxicity without the EGFR internalisation step, A431 cells 
were seed in triplicates in 96 well plares at a density of 4000 cells per well in 100 µl, 24 h prior 
to treatment. The medium was then replaced with increasing concentrations of Ru-NB for 44 h. 
Cells used for the light cytotoxicity experiments with Ru-NB were exposed to 480 nm light for 
6 x 3.5 min with 15 min gap in between irradiations or in a 96-well plate using a LUMOS-BIO 
photoreactor (Atlas Photonics). Each well was individually illuminated with a 5 lm LED at 
constant current (6.741 J cm-2). After 44 h in the incubator, the medium was replaced by fresh 
complete medium containing resazurin (0.2 mg mL-1 final concentration). After 4 h incubation 
at 37°C, the fluorescence signal of the resorufin product was read by SpectraMax M5 
mictroplate reader (ex: 540 nm em: 590 nm). IC50 values were calculated using GraphPad Prism 
software. 
 
Cellular ROS production 
10 cm cell culture plates were seeded with A431 cell line and allowed to adhere overnight. 
Next, the cells were incubated with a DCFH-DA solution (100 µM) in DMEM media for 30 
min at 37 ºC. Cells were then washed and treated with serum free DMEM media containing 
0.3% of BSA for 1 h at 37 ºC. The medium was then replaced in the plates with either Ru-NB 
dilution, 0.1 mM H2O2 or media. Cells were then incubated on ice for 1 h. After that time, the 
cells were transferred for 1 h at 37 ºC. The medium was then replaced by fresh complete 
medium. The cells used for the light experiments were exposed to 480 nm light for 3.5 min 
using a LUMOS-BIO photoreactor (Atlas Photonics; 1.124 J cm-2). All cells were then washed, 
collected and gated using Fortessa instrument in Cytometry Platform at the Curie Institute. 
Data was analysed using FlowJo 10.5.2 software.
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